Impact of High-Risk Cytogenetics and Achievement of Molecular Remission on Long-Term Freedom from Disease after Autologous-Allogeneic Tandem Transplantation in Patients with Multiple Myeloma

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 3, 2013, Pages 398-404

  Kröger, Nicolaus ^a   Badbaran, Anita ^a   Zabelina, Tatjana ^a   Ayuk, Francis ^a   Wolschke, Christine ^a   Alchalby, Haefaa ^a   Klyuchnikov, Evgeny ^a   Atanackovic, Djordje ^a   Schilling, Georgia ^a   Hansen, Timon ^a   Schwarz, Sabine ^a   Heinzelmann, Marion ^a   Zeschke, Silke ^a   Bacher, Ulrike ^a   Stübig, Thomas ^a   Fehse, Boris ^a   Zander, Axel R ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

ASO primer; Graft versus host disease; Plasma cell chimerism; Unrelated donor

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; IDARUBICIN; MELPHALAN; VINCRISTINE;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CYTOGENETICS; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INDUCTION CHEMOTHERAPY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; CYTOGENETIC ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; MYELOABLATIVE AGONISTS; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; TRANSLOCATION, GENETIC; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE;

EID: 84873737833     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.10.008     Document Type: Article

References (39)

1. Lahuerta J.J., Martinez-Lopez J., Serna J.D., et al. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000, 109:438-446.
2. Martinez-Lopez J., Blade J., de la Rubia J., et al. Prognostic impact of posttransplantation complete remission in multiple myeloma: final results of a prospective study in a series of homogenously treated patients. Haematologica 2007, 92. abstract 42.
3. Corradini P., Voena C., Tarella C., et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999, 17:208-215.
4. Martinelli G., Terragna C., Zamagni E., et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 2000, 18:2273-2281.
5. Corradini P., Cavo M., Lokhorst H., et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003, 102:1927-1929. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
6. Kröger N., Schwerdtfeger R., Kiehl M., et al. Autologous stem cell transplantation followed by dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002, 100:755-760.
7. Maloney D.G., Molina A.J., Sahebi F., et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003, 102:3447-3454.
8. Garban F., Attal M., Michallet M., et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006, 107:3474-3480.
9. Bruno B., Rotta M., Patriarca F., et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007, 356:1110-1120.
10. Rosinol L., Perez-Simon J.A., Sureda A., et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008, 112:3591-3593.
11. Gahrton G., Bjorkstrand B., Iacobelli S., et al. Tandem autologous (ASCT)/allogeneic reduced-intensity conditioning transplantation (RIC) with identical sibling donor versus ASCT in previously untreated multiple myeloma (MM): long-term follow-up of a prospective controlled trial by the EBMT. Blood 2009, 114. abstract 52.
12. Krishnan A., Pasquini M.C., Ewell M., et al. Tandem autologous hematopoietic stem cell transplants (AuHCT) with or without maintenance therapy (auto-auto) versus single AuHCT followed by HLA-matched sibling non-myeloablative allogeneic HCT (auto-allo) for patients with standard risk (SR) multiple myeloma (MM): results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial. Blood 2010, 116. abstract 41.
13. Björkstrand B., Iacobelli S., Hegenbart U., et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol 2011, 29:3016-3022.
14. Avet-Loiseau H., Leleu X., Roussel M., et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010, 28:4630-4634.
15. Avet-Loiseau H., Attal M., Campion L., et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol 2012, 30:1949-1952.
16. Munshi N.C., Anderson K.C., Bergsagel P.L., et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011, 117:4696-4700.
17. Neben K., Lokhorst H.M., Jauch A., et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012, 119:940-948.
18. Bladé J., Samson D., Reece D., et al. Myeloma Subcommittee of the European Group for Blood and Marrow Transplant. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998, 102:1115-1123.
19. Tögel F., Kröger N., Korioth F., et al. Molecular methods for detection and quantification of myeloma cells after bone marrow transplantation: comparison between real-time quantitative and nested PCR. J Hematother 2002, 11:971-976.
20. Kröger N., Zagrivnaja M., Schwartz S., et al. Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma. Exp Hematol 2006, 34:688-693.
21. Alizadeh M., Bernard M., Danic B., et al. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood 2002, 99:4618-4625.
22. Fehse B., Chukhlovin A., Kühlcke K., et al. Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation. J Hematother Stem Cell Res 2001, 10:419-425.
23. Harousseau J.L., Attal M., Avet-Loiseau H. The role of complete remission in multiple myeloma. Blood 2009, 114:3139-3146.
24. Hoering A., Crowley J., Shaughnessy J.D., et al. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols. Blood 2009, 114:1299-1305.
25. Ladetto M., Pagliano G., Ferrero S., et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010, 28:2077-2084.
26. Gahrton G., Tura S., Ljungman P., et al. Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med 1991, 325:1267-1273.
27. Gahrton G., Svenssin H., Cavo M., et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed in 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001, 113:209-216.
28. Moreau P., Garban F., Attal M., et al. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood 2008, 112:3914-3915.
29. Galimberti S., Benedetti E., Morabito F., et al. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leuk Res 2005, 29:961-966.
30. Durie B.G., Harousseau J.L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
31. Kröger N., Asenova S., Gerritzen A., et al. Questionable role of free light chain assay ratio to determine stringent complete remission in multiple myeloma patients. Blood 2010, 115:3413-3414.
32. Pavia B., Martinez-Lopez J., Vidirales M.B., et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol 2011, 29:1627-1633.
33. Lioznov M., Badbaran A., Fehse B., et al. Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs. PCR-based techniques. Bone Marrow Transplant 2008, 41:913-916.
34. Schilling G., Hansen T., Shimoni A., et al. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2008, 22:1250-1255.
35. Kröger N., Schilling G., Einsele H., et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood 2004, 103:4056-4061.
36. Roos-Weil D., Moreau P., Avet-Loiseau H., et al. Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Haematologica 2011, 96:1504-1511.
37. Kröger N., Sayer H.G., Schwerdtfeger R., et al. Unrelated stem cell transplantation in multiple myeloma after reduced-intensity conditioning with pre-transplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002, 100:3919-3924.
38. Kröger N., Badbaran A., Lioznov M., et al. Post-transplant immunotherapy with donor-lymphocyte infusions and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Hematol 2009, 37:791-798.
39. Kröger N., Shimoni A., Zagrivnaja M., et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004, 104:3361-3363.